Skip to main content
. Author manuscript; available in PMC: 2011 Oct 24.
Published in final edited form as: J Orthop Res. 2010 Oct;28(10):1330–1337. doi: 10.1002/jor.21126

Figure 2.

Figure 2

Alkaline phosphatase activity for genetically modified human (top) and equine (bottom) BMDMSCs for each of the 5 different treatment groups. AdBMP-2 elicits the greatest effect on ALP production. Different letters indicate significant (P<0.05) differences among groups.